TIGIT and neoplasm: As exemplarily shown in Fig. 3E, a significant co-expression pattern of TIGIT and PVRIG was detected in the CD56−CD16+NK cells and of CD39 and CD73 within the CD56+CD16−NK cell subset, which reached statistical significance in at least 2 of 4 tumor entities (Fig. 3F).